<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137879">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925781</url>
  </required_header>
  <id_info>
    <org_study_id>13-16684</org_study_id>
    <nct_id>NCT01925781</nct_id>
  </id_info>
  <brief_title>e-Cigarettes Versus NRT Gum for Smoking Cessation</brief_title>
  <official_title>e-Cigarettes Versus Nicotine Replacement Therapy for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial comparing electronic cigarettes (e-Cigarettes) to nicotine gum
      for smoking cessation. Participants will be randomly assigned to either e-cigarette use or
      nicotine gum use during a quit attempt. All participants will have a one hour meeting with a
      tobacco treatment specialist to develop a quit plan and set a quit date. Quit status will be
      determined at 12 weeks after the quit date. Continued use of nicotine replacement (either
      e-Cigarette or nicotine gum) and satisfaction with the treatment assignment will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IND required
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Sustained abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>No smoking at 12 weeks after the predetermined quit date with a 5 day grace period. Self-report will be biochemically confirmed with expired carbon monoxide (CO) and salivary cotinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Continued use of nicotine replacement</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Continued use of nicotine in non-cigarette form (e-cigarette or gum) at 12 weeks after the quit date. Will be biochemical determined from salivary cotinine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Point prevalence abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>No smoking in the previous 7 days. Self report will be biochemically confirmed with expired CO and salivary cotinine.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight change</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in weight at 12 weeks after the quit date</description>
  </other_outcome>
  <other_outcome>
    <measure>Satisfaction with the assigned treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Satisfaction with the assigned treatment will be assessed on a Likert scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Nicotine Addiction</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>e-Cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STAM 1100mAh CE4 eGo Clearomizer e-Cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine polacrilex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine Replacement gum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine polacrilex</intervention_name>
    <description>2 mg and 4 mg gum will be used according to the FDA approved product labelling</description>
    <arm_group_label>Nicotine polacrilex</arm_group_label>
    <other_name>Nicotine Gum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STAM 1100mAh CE4 eGo Clearomizer</intervention_name>
    <arm_group_label>e-Cigarette</arm_group_label>
    <other_name>e-Cigarette</other_name>
    <other_name>electronic nicotine delivery device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smokes at least five cigarettes per day

          -  No current or previous regular use of e-cigarettes

          -  Ready to quit smoking

        Exclusion Criteria:

          -  Use of smokeless or pipe tobacco

          -  Smoke more than 40 cigarettes per day

          -  Pregnant or breastfeeding

          -  Unable to chew gum due to dental or jaw problems

          -  Myocardial infarction (heart attack) within the previous 12 months

          -  Hypersensitivity to propylene glycol or nicotine gum
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy J Arouni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine Addiction</keyword>
  <keyword>e-Cigarette</keyword>
  <keyword>electronic nicotine delivery device</keyword>
  <keyword>electronic cigarette</keyword>
  <keyword>nicotine replacement therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Smoking</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
